Standardisation of minimal residual disease in multiple myeloma

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

(2017) Cristina Jiménez et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

(2017) J Flores-Montero et al.   LEUKEMIA

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

(2017) Nikhil C. Munshi et al.   JAMA Oncology

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

(2016) B. Paiva et al.   BLOOD

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

(2016) B. Paiva et al.   BLOOD

Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients

(2016) Karen Shires et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study

(2016) Iole Cordone et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes

(2016) Yinlei Bai et al.   Journal of Hematology & Oncology

11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement

(2016) Constantin Lapa et al.   Theranostics

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality

(2015) J. Martinez-Lopez et al.   BLOOD

New criteria for response assessment: role of minimal residual disease in multiple myeloma

(2015) B. Paiva et al.   BLOOD

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

(2015) A. C. Rawstron et al.   BLOOD

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma

(2015) E. Zamagni et al.   CLINICAL CANCER RESEARCH

Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?

(2015) B. Paiva et al.   CLINICAL CANCER RESEARCH

Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration

(2015) H. R. Bergen et al.   CLINICAL CHEMISTRY

Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases

(2015) Fanny Pojero et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service

(2015) Andy C. Rawstron et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of “normal” residual plasma cell analysis

(2015) Fanny Pojero et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

(2015) Maryalice Stetler-Stevenson et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

(2015) Juan Flores-Montero et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma

(2015) K. Philipp-Abbrederis et al.   EMBO Molecular Medicine

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

(2015) R. M. de Tute et al.   HAEMATOLOGICA

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

(2015) Meletios A. Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma

(2015) Daniela Drandi et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease

(2015) K. Herrmann et al.   JOURNAL OF NUCLEAR MEDICINE

The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution

(2015) N Puig et al.   LEUKEMIA

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

(2015) Sham Mailankody et al.   Nature Reviews Clinical Oncology

Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma

(2015) M B Meads et al.   ONCOGENE

Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia

(2015) Jizhong Liu et al.   Oncotarget

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)

(2015) Carolina Terragna et al.   Oncotarget

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma

(2015) Sara Yousef et al.   Human Vaccines & Immunotherapeutics

Deep Response in Multiple Myeloma: A Critical Review

(2015) Mariateresa Fulciniti et al.   Biomed Research International

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

(2015) R. M. de Tute et al.   HAEMATOLOGICA

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

(2015) Neha Korde et al.   JAMA Oncology

The Use of MAGE C1 and Flow Cytometry to Determine the Malignant Cell Type in Multiple Myeloma

(2015) Kirsty Wienand et al.   PLoS One

α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma

(2015) Katharina Teiluf et al.   Oncotarget

Utility of Nine-Color, 11-Parameter Flow Cytometry for Detection of Plasma Cell Neoplasms

(2014) Amir Behdad et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

(2014) Ola Landgren et al.   AMERICAN JOURNAL OF HEMATOLOGY

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

(2014) J. Martinez-Lopez et al.   BLOOD

Curing myeloma at last: defining criteria and providing the evidence

(2014) B. Barlogie et al.   BLOOD

Robust isolation of malignant plasma cells in multiple myeloma

(2014) I. Frigyesi et al.   BLOOD

Quantification of clonal circulating plasma cells in relapsed multiple myeloma

(2014) Wilson I. Gonsalves et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Cancer Stem Cell Hypothesis: A Guide to Potential Molecular Targets

(2014) Alessandro Allegra et al.   CANCER INVESTIGATION

State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings

(2014) Charles Mesguich et al.   EUROPEAN JOURNAL OF RADIOLOGY

ComplexIGHrearrangements in multiple myeloma: Frequent detection discrepancies among three different probe sets

(2014) Gina Y. Kim et al.   GENES CHROMOSOMES & CANCER

In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes

(2014) Erming Tian et al.   GENES CHROMOSOMES & CANCER

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma

(2014) B. Paiva et al.   HAEMATOLOGICA

Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma

(2014) Sang-Yong Shin et al.   JOURNAL OF CLINICAL LABORATORY ANALYSIS

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

(2014) Murielle Roussel et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR

(2014) Lawrence J. Jennings et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Monitoring M-Proteins in Patients with Multiple Myeloma Using Heavy-Chain Variable Region Clonotypic Peptides and LC–MS/MS

(2014) David R. Barnidge et al.   JOURNAL OF PROTEOME RESEARCH

Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy

(2014) David R. Barnidge et al.   JOURNAL OF PROTEOME RESEARCH

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

(2014) L Melchor et al.   LEUKEMIA

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

(2014) T Paíno et al.   LEUKEMIA

Low-energy laser irradiation promotes cellular damage in glucocorticoid-resistant multiple myeloma cells

(2014) Alessandro Allegra et al.   LEUKEMIA & LYMPHOMA

Comparison of Droplet Digital PCR and Seminested Real-Time PCR for Quantification of Cell-Associated HIV-1 RNA

(2014) Maja Kiselinova et al.   PLoS One

Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia

(2014) Ju Bai et al.   Proteome Science

Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients

(2014) Elizabeth R. Remily-Wood et al.   Proteomics Clinical Applications

Response evaluation and monitoring of multiple myeloma

(2014) Carlos Fernández de Larrea et al.   Expert Review of Hematology

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma

(2014) R Silvennoinen et al.   Blood Cancer Journal

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

(2014) B A Walker et al.   Blood Cancer Journal

Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques

(2014) Noa Biran et al.   Current Hematologic Malignancy Reports

Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma

(2013) Mark Korthals et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma

(2013) Jacob Smeltzer et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

(2013) A. Flanders et al.   BLOOD

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

(2013) B. Paiva et al.   BLOOD

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

(2013) S. Z. Usmani et al.   BLOOD

Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial

(2013) Treen C. M. Morris et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies

(2013) D. J. Green et al.   CANCER RESEARCH

Digital PCR as a Novel Technology and Its Potential Implications for Molecular Diagnostics

(2013) J. F. Huggett et al.   CLINICAL CHEMISTRY

CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma

(2013) André Veillette et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma

(2013) Alessandro Allegra et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma

(2013) Prashant Kapoor et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease in Multiple Myeloma

(2013) Nikhil C. Munshi et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group

(2013) Maxime Janin et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

(2013) N Puig et al.   LEUKEMIA

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

(2013) M Ladetto et al.   LEUKEMIA

Association of response endpoints with survival outcomes in multiple myeloma

(2013) S Lonial et al.   LEUKEMIA

New orally active proteasome inhibitors in multiple myeloma

(2013) Alessandro Allegra et al.   LEUKEMIA RESEARCH

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases

(2013) Prashant R. Tembhare et al.   LEUKEMIA RESEARCH

Absolute quantification by droplet digital PCR versus analog real-time PCR

(2013) Christopher M Hindson et al.   NATURE METHODS

Highly Precise Measurement of HIV DNA by Droplet Digital PCR

(2013) Matthew C. Strain et al.   PLoS One

Overview of clinical flow cytometry data analysis: recent advances and future challenges

(2013) Carlos E. Pedreira et al.   TRENDS IN BIOTECHNOLOGY

Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia

(2013) WEI SONG et al.   Oncology Letters

Prognostic Impact of Serum Immunoglobulin Heavy/Light Chain Ratio in Patients with Multiple Myeloma in Complete Remission after Autologous Stem Cell Transplantation

(2012) Natalia Tovar et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma

(2012) A. Chaidos et al.   BLOOD

IMWG consensus on maintenance therapy in multiple myeloma

(2012) H. Ludwig et al.   BLOOD

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

(2012) S. Kumar et al.   BLOOD

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma

(2012) Noemí Puig et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation

(2012) Peter Bannas et al.   EUROPEAN RADIOLOGY

Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation

(2012) Thorsten Derlin et al.   EUROPEAN RADIOLOGY

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

(2012) R. J. Pessoa de Magalhaes et al.   HAEMATOLOGICA

CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype

(2012) T. Paino et al.   HAEMATOLOGICA

Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma

(2012) J. Hillengass et al.   HAEMATOLOGICA

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide

(2012) YAWARA KAWANO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Comparison of Droplet Digital PCR to Real-Time PCR for Quantitative Detection of Cytomegalovirus

(2012) R. T. Hayden et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma

(2012) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

(2012) N Hosen et al.   LEUKEMIA

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

(2012) G Bianchi et al.   LEUKEMIA

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

(2012) T Kalina et al.   LEUKEMIA

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients

(2012) A Bradwell et al.   LEUKEMIA

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients

(2012) H Ludwig et al.   LEUKEMIA

FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma

(2012) K. Elkins et al.   MOLECULAR CANCER THERAPEUTICS

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic Usefulness and Prognostic Impact of CD200 Expression in Lymphoid Malignancies and Plasma Cell Myeloma

(2011) Daisy Alapat et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter

(2011) Mark Korthals et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

(2011) B. Paiva et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

(2011) M. Cavo et al.   BLOOD

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

(2011) F. Gay et al.   BLOOD

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

(2011) E. Zamagni et al.   BLOOD

The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients

(2011) David Chiron et al.   BRITISH JOURNAL OF HAEMATOLOGY

Roadmap for Harmonization of Clinical Laboratory Measurement Procedures

(2011) W. Greg Miller et al.   CLINICAL CHEMISTRY

Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma*

(2011) Brian M. Elliott et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma

(2011) D. Atanackovic et al.   HAEMATOLOGICA

Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach

(2011) Joan Bladé et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

(2011) B Paiva et al.   LEUKEMIA

Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis

(2011) S Pfeifer et al.   LEUKEMIA

An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions

(2010) Lennard J. M. Dekker et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

(2010) J.-L. Harousseau et al.   BLOOD

Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors

(2010) Alessandro Allegra et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents

(2010) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition

(2009) C. F. de Larrea et al.   BLOOD

The role of complete response in multiple myeloma

(2009) J.-L. Harousseau et al.   BLOOD

The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma

(2009) C. E. Chee et al.   BLOOD

The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios

(2009) S. Singhal et al.   BLOOD

Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients

(2009) G. P. Mead et al.   BLOOD

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

(2009) T. B. Bartel et al.   BLOOD

Serum Free Light Chain Ratio, Total  /  Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

(2009) M. M. Giarin et al.   CLINICAL CHEMISTRY

Constitutively lower expressions of CD54 on primary myeloma cells and their different localizations in bone marrow

(2009) Mohd S. Iqbal et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

(2009) M Dimopoulos et al.   LEUKEMIA

Environmental-mediated drug resistance: a target for multiple myeloma therapy

(2009) Kenneth H Shain et al.   Expert Review of Hematology

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD

Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques

(2008) M Lioznov et al.   BONE MARROW TRANSPLANTATION

Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response

(2008) Pilar Martínez-Sánchez et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

(2008) W. Matsui et al.   CANCER RESEARCH

MAGE-C1/CT-7 expression in plasma cell myeloma: Sub-cellular localization impacts on clinical outcome

(2008) M. Tinguely et al.   CANCER SCIENCE

Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney Disease

(2008) C. A. Hutchison et al.   Clinical Journal of the American Society of Nephrology

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

(2008) A. C. Rawstron et al.   HAEMATOLOGICA

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

(2008) Gema Mateo et al.   JOURNAL OF CLINICAL ONCOLOGY

18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma

(2008) R. Fonti et al.   JOURNAL OF NUCLEAR MEDICINE

Go with the flowfor monitoring response in myeloma with minimal residual disease

(2008) Kylie D. Mason et al.   LEUKEMIA & LYMPHOMA

Haematopoietic stem cell release is regulated by circadian oscillations

(2008) Simón Méndez-Ferrer et al.   NATURE

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE

Serum protein expression profiling in pediatric Hodgkin lymphoma: A report from the Children's Oncology Group

(2008) Lining Qi et al.   PEDIATRIC BLOOD & CANCER